Impact of ethnicity and race on treatment response: Past, present and future

Current Hepatitis Reports

Volumn 11, Issue 3, 2012, Pages 128-135

  Rodríguez Torres, Maribel ^a,b   Hallman, Deana ^a,c  

^a Fundación de Investigación   (Puerto Rico)

^b PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

African Americans; Asians; Chronic Hepatitis C; Ethnicity; Latinos; Race; Treatment response

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; TELAPREVIR;

AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASIAN; DIABETES MELLITUS; DRUG ABUSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ETHNICITY; FATIGUE; FUTUROLOGY; HEPATITIS C; HEPATITIS C VIRUS; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIVER CIRRHOSIS; NAUSEA; OUTCOME ASSESSMENT; PUBLIC HEALTH PROBLEM; RACE DIFFERENCE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84872184287     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-012-0134-6     Document Type: Article

References (44)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107-15.
2. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int. 2011;31:1-3.
3. Kershenobich D, Razavi HA, Sanchez-Avila JF, et al. Trends and projections of HCV epidemiology in Latin America. Liver Int. 2011;31 Suppl 2:18-29.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-65. (Pubitemid 32913521)
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-82.
6. Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-55.
7. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-93.
8. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135:821-9.
9. Asselah T, Estrabaud E, Bieche I, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010;30(9):1259-69.
10. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology. 1999;30(3):787-93. (Pubitemid 29409425)
11. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology. 2000;119:1317-23.
12. Jeffers LJ, Cassidy W, Howell CD, et al. Peginterferon alfa-2a (40 KD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-8. (Pubitemid 38702672)
13. Muir AJ, Bornstein JD, Killenberg PG, Atlantic Coast Hepatitis Treatment Group, et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-71. (Pubitemid 38669209)
14. Conjeevaram HS, Fried MW, Jeffers LJ, Virahep-C Study Group, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131(2):470-7. AA response to pegIFN/RBV treatment, compared to Caucasians. (Pubitemid 44142464)
15. Schiffman M, Mihas A, Millwala F, et al. Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3. Am J Gastroenterol. 2007;102:761-6. (Pubitemid 46496627)
16. Layden-Almer JE, Ribeiro RM, Wiley T, et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. epatology. 2003;37 (6):1343-50. (Pubitemid 36667314)
17. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450-6. (Pubitemid 30484478)
18. Ioannou GN, Dominitz JA, Weiss NS, et al. Racial differences in the relationship between hepatitis C infection and iron stores. Hepatology. 2003;37:795-801. (Pubitemid 36397390)
19. Thio CL, Thomas DL, Goedert JJ, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis. 2001;184:16-21. (Pubitemid 32568495)
20. Kimball P, Elswick RK, Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol. 2001;65:510-6. (Pubitemid 32959077)
21. Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology. 2003;37:590-9. (Pubitemid 36258781)
22. Jacobson I, Brown R, McCone J, et al. Impact of weight-based ribavarin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007;46:982-90. (Pubitemid 350144762)
23. Conjeevaram H, Kleiner D, Everhart J, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80-7. (Pubitemid 46144367)
24. YuML, ChuangWL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24(3):336-45.
25. Hepburn MJ, Hepburn LM, Cantu NS, et al. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med. 2004;117(3):163-8. Early study to document the different response rates among ethnic and racial groups. (Pubitemid 39055867)
26. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavarin in chronic hepatitis C. Am J Gastroenterol. 2007;102:2181-8. (Pubitemid 47493845)
27. Pattullo V, Heathcote EJ, Wong DK. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. Hepatol Int. 2010;4(4):723-31.
28. Hu KQ, Freilich B, Brown RS, et al. Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. J Clin Gastroenterol. 2011;45(8):720-6.
29. Gaglio PJ, Rodriguez-Torres M, Herring R, et al. Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy. J Clin Gastroenterol. 2004;38(7):599-604. (Pubitemid 38955419)
30. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Latino Study Group, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;15 (3):257-67. Only prospective multi-site study to examine impact of Latino ethnicity on response.
31. Balart LA, Lisker-Melman M, Hamzeh FM, LATINO study investigators, et al. Peginterferon α-2a plus ribavirin in Latino and Non- Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study. Am J Gastroenterol. 2010;105(10):2177-85.
32. Rodríguez-Torres M, Ríos-Bedoya CF, Rodríguez-Orengo J, et al. Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender. J Clin Gastroenterol. 2006;40 (4):358-66. (Pubitemid 44309530)
33. Rodríguez-Torres M. Latinos and chronic hepatitis C: a singular population. Clin Gastroenterol Hepatol. 2008;6(5):484-90. (Pubitemid 351609457)
34. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
35. Yu S, Douglass JM, Qualis, et al. Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in Hispanics compared to non-Hispanic whites. Am J Gastroenterol. 2009;104:1686-92.
36. Telaprevir (package insert) INCIVEK™(package insert) Cambridge: Vertex Pharmaceuticals Incorporated; 2011.
37. Boceprevir (package insert) VICTRELIS (package insert)
38. Jacobson IM, McHutchison JG, Dusheiko G, ADVANCE Study Team, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-16. Pivotal study of Telaprevir based therapy in naives.
39. Sherman KE, Flamm SL, Afdhal NH, ILLUMINATE Study Team, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365 (11):1014-24. Pivotal study for Telaprevir.
40. Dusheiko GM, Fried MW, Reddy R, et al Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response rates in treatment-naïve patients regardless of race or ethnicity. Presented at: 46th annual meeting of the European Association for the Study of the Liver. Berlin, Germany; April 2011. Telaprevir impact on response in ethnic and racial groups.
41. Muir AJ, Sullivan JC, Dusheiko GM, et al. ADVANCE and ILLUMINATE Study Teams Treatment Effect and Resistance Profiles Were Similar Between Black/African American and Non-Black/African American Patients Treated with a Telaprevir Combination Regimen Presented at: 76th Annual Meeting of American College of Gastroenterology. Washington DC; October, 2011. Detailed analysis of black/AA responses with Telaprevir based therapy.
42. Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206. Pivotal study of Boceprevir based therapy in naives.
43. Anna Suk-Fong Lok Presented at: 46th annual meeting of the European Association for the Study of the Liver. Berlin, Germany; April 2011. First report of cure of patients with IFN/RBV free therapy.
44. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55 (3):742-8. Further report of 100% SVR in all patients that received therapy with genotype 1b patients with 2 oral drugs combination.